The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Open accessAbstract
Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen implicated in tumor invasion, which is highly expressed in mesothelioma and lung, pancreas, breast, ovarian, and other cancers. Its low-level expression in mesothelia, however, commands thoughtful therapeutic interventions. Encouragingly, recent clinical trials evaluating active immunization or immunoconjugates in patients with pancreatic adenocarcinoma or mesothelioma have shown responses without toxicity. Altogether, these findings and preclinical CAR therapy models using either systemic or regional T-cell delivery argue favorably for mesothelin CAR therapy in multiple solid tumors. Significance: Recent success obtained with adoptive transfer of CAR T cells targeting CD19 in patients with refractory hematologic malignancies has generated much enthusiasm for T-cell engineering and raises the prospect of implementing similar strategies for solid tumors. Mesothelin is expressed in a wide range and a high percentage of solid tumors, which we review here in detail. Mesothelin CAR therapy has the potential to treat multiple solid malignancies. Cancer Discov; 6(2); 133–46. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationZhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Self-citationHeparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Self-citationJohn, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Self-citationLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Self-citationHoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Self-citationImmunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Self-citationMoon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationDi Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Application of Mesothelin Immunostaining in Tumor Diagnosis
Ordóñez, N. G. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200311000-00003 · Cited by 382
Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0869 · Cited by 379
Le, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 315
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
Self-citationSampson, J. H., Choi, B. D., Sanchez-Perez, L., Suryadevara, C. M., Snyder, D. J., Flores, C. T., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 291
Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Mesothelin Is Not Required for Normal Mouse Development or Reproduction
Bera, T. K., & Pastan, I. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2902-2906.2000 · Cited by 253
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Golfier, S., Kopitz, C., Kahnert, A., Heisler, I., Schatz, C. A., Stelte-Ludwig, B., Mayer-Bartschmid, A., Unterschemmann, K., Bruder, S., Linden, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0926 · Cited by 249
Hassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A., Kreitman, R. J., Miettinen, M. M., Steinberg, S. M., Fowler, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006941 · Cited by 234
Chen, S.-H., Hung, W.-C., Wang, P., Paul, C., & Konstantopoulos, K. (2013) · Scientific Reports · doi:10.1038/srep01870 · Cited by 231
Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., DeMatteo, R. P., Ayala, A., Joseph Espat, N., Junghans, R. P., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1692-6 · Cited by 230
Markley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228
Self-citationCAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 227
Self-citationPhase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Kreitman, R. J., Hassan, R., FitzGerald, D. J., & Pastan, I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0062 · Cited by 222
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217
Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Servais, E. L., Colovos, C., Rodriguez, L., Bograd, A. J., Nitadori, J.-I., Sima, C., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2614 · Cited by 202
Self-citationHassan, R., Cohen, S. J., Phillips, M., Pastan, I., Sharon, E., Kelly, R. J., Schweizer, C., Weil, S., & Laheru, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2275 · Cited by 201
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
Loskog, A., Giandomenico, V, Rossig, C., Pule, M., Dotti, G., & Brenner, M. K. (2006) · Leukemia · doi:10.1038/sj.leu.2404366 · Cited by 192
CAR T Cells for Solid Tumors: Armed and Ready to Go?
Kakarla, S., & Gottschalk, S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 190
Wilkie, S., Burbridge, S. E., Chiapero-Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., & Maher, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127951 · Cited by 189
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187
Kachala, S. S., Bograd, A. J., Villena-Vargas, J., Suzuki, K., Servais, E. L., Kadota, K., Chou, J., Sima, C. S., Vertes, E., Rusch, V. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1862 · Cited by 185
Self-citationProsser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 184
Hassan, R., Kindler, H. L., Jahan, T., Bazhenova, L., Reck, M., Thomas, A., Pastan, I., Parno, J., O'Shannessy, D. J., Fatato, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0804 · Cited by 180
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Tchou, J., Wang, L.-C., Selven, B., Zhang, H., Conejo-Garcia, J., Borghaei, H., Kalos, M., Vondeheide, R. H., Albelda, S. M., June, C. H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2018-4 · Cited by 172
Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 170
Hassan, R., Sharon, E., Thomas, A., Zhang, J., Ling, A., Miettinen, M., Kreitman, R. J., Steinberg, S. M., Hollevoet, K., & Pastan, I. (2014) · Cancer · doi:10.1002/cncr.28875 · Cited by 168
Beard, R. E., Zheng, Z., Lagisetty, K. H., Burns, W. R., Tran, E., Hewitt, S. M., Abate-Daga, D., Rosati, S. F., Fine, H. A., Ferrone, S., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-25 · Cited by 163
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
Ho, W., Blattman, J. N., Dossett, M. L., Yee, C., & Greenberg, P. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00113-2 · Cited by 157
Hombach, A. A., & Abken, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25960 · Cited by 152
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-106 · Cited by 151 · cited 1×
“Overexpression of MSLN alone is sufficient to constitutively activate the NFκB, MAPK, and PI3K intracellular pathways promoting cell proliferation and resistance to apoptosis (25).”
BackgroundHumoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
Ho, M., Hassan, R., Zhang, J., Wang, Q., Onda, M., Bera, T. K., & Pastan, I. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2304 · Cited by 149
Kofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 141
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Riese, M. J., Wang, L. S., Moon, E. K., Joshi, R. P., Ranganathan, A., June, C. H., Koretzky, G. A., & Albelda, S. Μ. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3874 · Cited by 135
Perna, S. K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M. K., Savoldo, B., & Dotti, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1016 · Cited by 134
Tozbikian, G. H., Brogi, E., Kadota, K., Catalano, J. P., Akram, M. M., Patil, S. N., Ho, A. Y., Reis-Filho, J. S., Weigelt, B., Norton, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114900 · Cited by 116
Self-citationAnkri, C., Shamalov, K., Horovitz‐Fried, M., Mauer, S., & Cohen, C. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203085 · Cited by 115
Wang, E., Wang, L.-C., Tsai, C., Bhoj, V. G., Gershenson, Z., Moon, E. K., Newick, K., Sun, J., Lo, A., Baradet, T. C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0054 · Cited by 115
NKG2D CARs as Cell Therapy for Cancer
Sentman, C. L., & Meehan, K. R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000029 · Cited by 111
Song, D.-G., Ye, Q., Santoro, S. P., Fang, C., Best, A. J., & Powell, D. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.143 · Cited by 108
Soluble mesothelin-related protein—A blood test for mesothelioma
Robinson, B. W. S., Creaney, J., Lake, R., Nowak, A. K., Musk, A. W., de Klerk, N. H., Winzell, P., Hellström, K. E., & Hellström, I. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.020 · Cited by 107
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 106
Self-citationNolan, K. F., Yun, C. O., Akamatsu, Y., et al. (1999) · PubMed · Cited by 99
Weijtens, M. E. M., Hart, E., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301051 · Cited by 95
Song, D.-G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4071 · Cited by 94
Zhang, L., Yu, Z., Muranski, P. J., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.75 · Cited by 93
Thomas, A., Chen, Y., Steinberg, S. M., Luo, J., Pack, S., Raffeld, M. A., Abdullaev, Z., Alewine, C., Rajan, A., Giaccone, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3429 · Cited by 89
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
Einama, T., Homma, S., Kamachi, H., Kawamata, F., Takahashi, K., Takahashi, N., Taniguchi, M., Kamiyama, T., Furukawa, H., Matsuno, Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.235 · Cited by 88
Emtage, P. C. R., Lo, A. S., Gomes, E. M., Liu, D. L., Gonzalo‐Daganzo, R. M., & Junghans, R. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4910 · Cited by 81
Willemsen, R., Debets, R., Hart, E., Hoogenboom, H. R., Bolhuis, R., & Chames, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301570 · Cited by 76
Condomines, M., Arnason, J. E., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130518 · Cited by 71
Self-citationKarlsson, S., Lindqvist, A. C., Fransson, M. E., Paul-Wetterberg, G., Nilsson, B., Essand, M., Nilsson, K., Frisk, P., Jernberg‐Wiklund, H., & Loskog, S. I. A. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.35 · Cited by 71
T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 69
Feng, Y., Xiao, X., Zhu, Z., Streaker, E. D., Ho, M., Pastan, I. H., & Dimitrov, D. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0945 · Cited by 62
A novel high‐affinity human monoclonal antibody to mesothelin
Ho, M., Feng, M., Fisher, R. J., Rader, C. M., & Pastan, I. H. (2010) · International Journal of Cancer · doi:10.1002/ijc.25557 · Cited by 60
Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer
Kobold, S., Steffen, J., Chaloupka, M., Grassmann, S. A., Henkel, J., Castoldi, R., Zeng, Y., Chmielewski, M. M., Schmollinger, J. C., Schnurr, M. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju364 · Cited by 53
Huye, L. E., Nakazawa, Y., Patel, M. P., Yvon, E. S., Sun, J., Savoldo, B., Wilson, M. H., Dotti, G., & Rooney, C. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.179 · Cited by 49
Asai, H., Fujiwara, H., An, J., Ochi, T., Miyazaki, Y., Nagai, K., Okamoto, S., Mineno, J., Kuzushima, K., Shiku, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056820 · Cited by 47
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
Peroz, C., Gauvrit, A., Barbieux, I., Padieu, M., Cellerin, L., Sagan, C., Scherpereel, A., Dabouis, G., & Grégoire, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00715.x · Cited by 46
Gargett, T., Fraser, C. K., Dotti, G., Yvon, E. S., & Brown, M. P. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000061 · Cited by 46
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer
Sanchez, C., Chan, R. C., Bajgain, P., Rambally, S., Palapattu, G. S., Mims, M. P., Rooney, C. M., Leen, A. M., Brenner, M. K., & Vera, J. F. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.49 · Cited by 44
Caruana, I., Weber, G., Ballard, B. C., Wood, M. S., Savoldo, B., & Dotti, G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2998 · Cited by 42
C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma
Kawamata, F., Homma, S., Kamachi, H., Einama, T., Kato, Y., Tsuda, M., Tanaka, S., Maeda, M., Kajino, K., Hino, O., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0773-6 · Cited by 40
Rizk, N. P., Servais, E. L., Tang, L. H., Sima, C. S., Gerdes, H., Fleisher, M., Rusch, V. W., & Adusumilli, P. S. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0993 · Cited by 40
Self-citationLamberts, L. E., de Groot, D. J. A., Bense, R. D., de Vries, E. G. E., & Fehrmann, R. S. N. (2015) · Oncotarget · doi:10.18632/oncotarget.4461 · Cited by 31
Chen, Y., Ayaru, L., Mathew, S., Morris, E. C., Pereira, S. P., & Behboudi, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088133 · Cited by 31
An In Vivo Platform for Tumor Biomarker Assessment
Servais, E. L., Suzuki, K., Colovos, C., Rodriguez, L., Sima, C. S., Fleisher, M., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026722 · Cited by 22
Self-citationModulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse
González, P. A., Carreño, L. J., Céspedes, P. F., Bueno, S. M., Riedel, C. A., & Kalergis, A. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/450291 · Cited by 17
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Villena‐Vargas, J., & Adusumilli, P. S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.03 · Cited by 16
Self-citationTranslational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma
Adusumilli, P. S. (2014) · Cancer · doi:10.1002/cncr.28883 · Cited by 4
Self-citation
Cited by
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Self-citationCAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Self-citationRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Role of Immunotherapy in Triple-Negative Breast Cancer
Keenan, T. E., & Tolaney, S. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7554 · Cited by 606
Metadata
- Authors
- Morello, A., Sadelain, M., & Adusumilli, P. S.
- Venue
- Cancer Discovery
- Published
- 2016-02-01
- Volume
- 6
- Issue
- 2
- Pages
- 133-146
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1926256541
- Cited by
- 477
- References
- 115
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.